Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

Bone Marrow Transplantation
Brian H KushnerF Boulad

Abstract

Topotecan appears to be relatively unaffected by the most common multidrug resistance mechanisms, may potentiate cytotoxicity of alkylators, has good penetration into the central nervous system, is active against a variety of neoplasms, and has myelosuppression as its paramount toxicity. We present our experience with a myeloablative regimen that includes topotecan. Twenty-one patients with poor-prognosis tumors and intact function of key organs received topotecan 2 mg/m2 by 30-min intravenous (i.v.) infusion on days -8, -7, -6, -5, -4; thiotepa 300 mg/m2 by 3 h i.v. infusion on days -8, -7, -6; and carboplatin by 4 h i.v. infusion on days -5, -4, -3 with a daily dose derived from the pediatric Calvert formula, using a targeted area under the curve of seven mg/ml* min ( approximately 500 mg/m2/day). Stem cell rescue was on day 0. The patients were 1 to 29 (median 4) years old; 18 were in complete remission (CR) and three in partial remission (PR). Early toxicities were severe mucositis and erythema with superficial peeling in all patients and a seizure, hypertension, and renal insufficiency followed by veno-occlusive disease in one patient each. Post-transplant treatment included radiotherapy alone (four patients) or plus biolo...Continue Reading

References

Nov 18, 1992·Journal of the National Cancer Institute·R J Motzer, G J Bosl
Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanD H Mahoney
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B H KushnerN K Cheung
May 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T C SheaW D Henner
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A MillerR L Schilsky
Mar 1, 1995·Cancer Treatment Reviews·E van der WallS Rodenhuis
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C B PrattJ T Sandlund
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G M BrodeurF Hedborg
Jun 5, 1996·Journal of the National Cancer Institute·S H KaufmannE K Rowinsky
Jun 19, 1996·Journal of the National Cancer Institute·S O'ReillyL B Grochow
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S O'ReillyL B Grochow
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR C Donehower
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R MurrenY C Cheng
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I J DunkelJ L Finlay
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L SaylorsT J Vietti
Nov 9, 2000·Medical and Pediatric Oncology·B H KushnerN K Cheung

❮ Previous
Next ❯

Citations

May 5, 2007·Journal of Cancer Research and Clinical Oncology·Thorsten SimonBarbara Hero
Jun 7, 2005·Cancer Letters·Anthony G McCluskeyRobert J Mairs
Oct 7, 2003·Journal of Pediatric Hematology/oncology·Robert I LiemRobert J Arceci
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey M VenstromKatharine C Hsu
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nai-Kong V CheungShakeel Modak
Jun 9, 2006·Expert Review of Anticancer Therapy·Maura Massimino, Veronica Biassoni
Feb 16, 2005·Expert Opinion on Drug Safety·Karen Seiter
Aug 6, 2004·Journal of Pharmaceutical Sciences·Markos LeggasClinton F Stewart
Nov 11, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Shakeel ModakNai-Kong V Cheung
Mar 17, 2005·Pediatric Blood & Cancer·Hyoung Soo ChoiHyo Seop Ahn
Nov 5, 2003·Medical and Pediatric Oncology·Brian H KushnerNai-Kong V Cheung
Nov 13, 2009·Pediatric Blood & Cancer·Ira J DunkelDavid H Abramson
May 21, 2010·Pediatric Blood & Cancer·Steven AllenCarlos Rodriguez-Galindo
May 21, 2010·Pediatric Blood & Cancer·Ira J DunkelDavid H Abramson
Mar 2, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Gilles Vassal
Feb 13, 2003·Pediatric Clinics of North America·Ulrike Reiss, Ellen Bolotin
Mar 26, 2015·Future Oncology·Jaume MoraJuan Rosai
Jan 18, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J MoraC de Torres
Jan 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nai-Kong V CheungIrene Y Cheung
Sep 4, 2009·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Megan Kinnear Lessig
Jan 14, 2009·Journal of Neuro-oncology·Thierry LesimpleYvon Guégan
Nov 4, 2016·International Journal of Surgical Pathology·Khin ThwayCyril Fisher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.